Medicine Overview of Fixvel 400mg+100mg Tablet
Fixvel is a combination of two antiviral medicines. This prescription medicine is used in the treatment of chronic hepatitis C virus (HCV) infection. It fights against the viruses to resolve the infection.
Fixvel should be taken in the prescribed dose and duration. It can be taken with or without food, but take it at the same time daily. It is advised not to consume more than the recommended dose. It is important to inform your doctor if you have any health conditions such as liver or kidney disease. It is harmful to consume alcohol along with this medicine, so it is advised to limit or avoid alcohol. The course of the medicine should be completed for better results.
The common side effects of this medicine are tiredness and headache. You should drink plenty of fluid and eat a healthy diet to prevent or overcome the side effects. Before taking the medicine, inform your doctor if you are taking any other medicines or supplements.
- Chronic hepatitis C virus (HCV) infection
- Headache
- Tiredness
-
Fixvel is used for the treatment of chronic hepatitis C virus (HCV) infection.
-
Take it with food, preferably at the same time everyday.
-
You will usually need to take this medicine every day for either 12 or 24 weeks.
-
Skipping doses increases the risk of treatment failure. Make sure that you take all your doses at the correct time.
-
It may cause fatigue, dizziness, and blurred vision. Don’t drive or do anything requiring concentration until you know how it affects you.
-
Fixvel may cause headaches. Drink plenty of water and take a suitable painkiller. Inform your doctor if it does not go away.
-
Your doctor may monitor your liver function and the amount of hepatitis C virus in your body regularly.
-
Do not stop taking this medicine without your doctor’s advice.
Oral
Adult
Chronic Hepatitis C
Indicated for adults with chronic hepatitis C virus (HCV) infection genotypes 1, 2, 3, 4, 5, and 6
1 tablet (400 mg sofosbuvir/ 100 mg velpatasvir) qDay
Patients without cirrhosis or with compensated cirrhosis (Child-Pugh A): Sofosbuvir/velpatasvir for 12 weeks
Patients with decompensated cirrhosis (Child-Pugh B or C): Sofosbuvir/velpatasvir plus weight-based ribavirin with food for 12 weeks
Hepatic impairment
Mild, moderate, or severe (Child-Pugh A, B, or C): No dosage adjustment required
Renal impairment
Severe renal impairment (eGFR <30mL/min/1.73 m²) or ESRD: No dosage recommendation can be give owing to higher exposures (up to 20-fold) of the predominant sofosbuvir metabolite
Sofosbuvir: Inhibitor of HCV NS5B RNA-dependent polymerase; its inhibition, in turn, suppresses viral replication
Velpatasvir: Pangenotypic HCV NS5A inhibitor; the NS5A protein is required for viral replication
Direct-acting antivirals (DDAs) may reactivate hepatitis B virus (HBV) in patients who have a current or previous HBV infection while being treated for hepatitis C virus
In a few cases, HBV reactivation in patients treated with DAA medicines resulted in serious liver problems or death
Patients should be screened for evidence of current or prior HBV infection before starting treatment with DAAs, and monitored for HBV flare-ups or reactivation during DAA treatment and posttreatment follow-up
Serious symptomatic bradycardia may occur if sofosbuvir is coadministered with amiodarone in combination with another direct-acting antiviral (eg, daclatasvir, simeprevir)
Lactation: Unknown if sofosbuvir, velpatasvir, or their metabolites are distributed in human breast milk
>10%
Without cirrhosis or with compensated cirrhosis
Headache (22%),Fatigue (15%)
With decompensated cirrhosis
Fatigue (32%),Anemia (26%),Hemoglobin <10 g/dL (23%),Nausea (15%),Headache 11%),Insomnia (11%)
1-10%
Without cirrhosis or with compensated cirrhosis
Nausea (9%),Asthenia (5%),Insomnia (5%),Lipase increase >3 x ULN (3%),Rash (2%),Depression (1%),Increased creatinine kinase >10 x ULN (1%)
With decompensated cirrhosis
Diarrhea (10%)
Hemoglobin <3.5 g/dL (7%),Rash (5%),Increased creatinine kinase ≥10 x ULN (2%)
Reviews
Clear filtersThere are no reviews yet.